Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Crump

Showing results (171-180 of 183) with videos related to

Pageof 19
Sort By:
Blood|May 12, 2016
Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphomaSarit E Assouline, Torsten Holm Nielsen, Stephen Yu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2016
Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell LymphomaMichael Crump, Sirpa Leppä, Luis Fayad, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 12, 2019
DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin LymphomaIan W Flinn, Carole B Miller, Kirit M Ardeshna, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2013
Prespecified candidate biomarkers identify follicular lymphoma patients who achieved longer progression-free survival with bortezomib-rituximab versus rituximabBertrand Coiffier, Weimin Li, Erin D Henitz, et al.
Blood Advances|June 27, 2020
Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphomaChristopher K Rushton, Sarah E Arthur, Miguel Alcaide, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 10, 2015
Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell LymphomasRyan D Morin, Sarit Assouline, Miguel Alcaide, et al.
Medrxiv : the Preprint Server for Health Sciences|March 22, 2023
Relapse timing is associated with distinct evolutionary dynamics in DLBCLLaura K Hilton, Henry S Ngu, Brett Collinge, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2023
Relapse Timing Is Associated With Distinct Evolutionary Dynamics in Diffuse Large B-Cell LymphomaLaura K Hilton, Henry S Ngu, Brett Collinge, et al.
Cancer Immunology, Immunotherapy : CII|February 13, 2019
Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2Linh T Nguyen, Samuel D Saibil, Valentin Sotov, et al.
Journal of Hematology & Oncology|December 16, 2023
Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North American Mantle Cell Lymphoma ConsortiumJulie M Vose, Kai Fu, Lu Wang, et al.
Pageof 19

Showing results (171-180 of 183) with videos related to

Sort By:
Pageof 19
Blood|May 12, 2016
Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphomaSarit E Assouline, Torsten Holm Nielsen, Stephen Yu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2016
Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell LymphomaMichael Crump, Sirpa Leppä, Luis Fayad, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 12, 2019
DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin LymphomaIan W Flinn, Carole B Miller, Kirit M Ardeshna, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2013
Prespecified candidate biomarkers identify follicular lymphoma patients who achieved longer progression-free survival with bortezomib-rituximab versus rituximabBertrand Coiffier, Weimin Li, Erin D Henitz, et al.
Blood Advances|June 27, 2020
Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphomaChristopher K Rushton, Sarah E Arthur, Miguel Alcaide, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 10, 2015
Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell LymphomasRyan D Morin, Sarit Assouline, Miguel Alcaide, et al.
Medrxiv : the Preprint Server for Health Sciences|March 22, 2023
Relapse timing is associated with distinct evolutionary dynamics in DLBCLLaura K Hilton, Henry S Ngu, Brett Collinge, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2023
Relapse Timing Is Associated With Distinct Evolutionary Dynamics in Diffuse Large B-Cell LymphomaLaura K Hilton, Henry S Ngu, Brett Collinge, et al.
Cancer Immunology, Immunotherapy : CII|February 13, 2019
Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2Linh T Nguyen, Samuel D Saibil, Valentin Sotov, et al.
Journal of Hematology & Oncology|December 16, 2023
Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North American Mantle Cell Lymphoma ConsortiumJulie M Vose, Kai Fu, Lu Wang, et al.
Pageof 19